Literature DB >> 31156816

Stability of daptomycin in peritoneal dialysis solutions packaged in dual-compartment infusion bags.

Sagar Ramdas1, Farzana Yousaf1, Madhur D Shastri1, Troy Wanandy1,2, Syed T R Zaidi1,2, Manish Khandagale3, Matthew Jose4,5, Rahul P Patel1.   

Abstract

BACKGROUND: Intraperitoneal daptomycin is used for the treatment of peritoneal dialysis (PD)-associated peritonitis caused by vancomycin-resistant bacteria. This study investigated the stability of daptomycin in a pH-neutral PD solution.
METHODS: Reconstituted solution of daptomycin was added to a total of nine PD bags to obtain a concentration of 20 mg/L and stored at 1 of 3 different temperatures: 4 or 25°C for up to 168 h or 37°C for up to 48 h. Stabilities were determined by visual inspection, pH measurement and high-performance liquid chromatography.
RESULTS: Daptomycin retained more than 90% of its initial concentration for 120, 72 and 12 h at 4°C, 25°C and 37°C, respectively. No physical precipitation or pH change was observed during the study.
CONCLUSIONS: Daptomycin in a pH-neutral PD solution is physically and chemically stable for 120 and 12 h at 4°C and 37°C, respectively.

Entities:  

Year:  2015        PMID: 31156816      PMCID: PMC6451525          DOI: 10.1136/ejhpharm-2015-000651

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  11 in total

1.  Peritoneal dialysis-related infections recommendations: 2010 update.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Judith Bernardini; Ana E Figueiredo; Amit Gupta; David W Johnson; Ed J Kuijper; Wai-Choong Lye; William Salzer; Franz Schaefer; Dirk G Struijk
Journal:  Perit Dial Int       Date:  2010 Jul-Aug       Impact factor: 1.756

Review 2.  Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use.

Authors:  Filip de Vin; Peter Rutherford; Dirk Faict
Journal:  Perit Dial Int       Date:  2009 Jan-Feb       Impact factor: 1.756

3.  Intraperitoneal daptomycin used to successfully treat vancomycin-resistant enterococcus peritonitis.

Authors:  A A Hassoun; R W Coomer; L Mendez-Vigo
Journal:  Perit Dial Int       Date:  2009 Nov-Dec       Impact factor: 1.756

4.  Peritoneal dialysis-related peritonitis caused by vancomycin-resistant Enterococcus faecium.

Authors:  Aydin Unal; Cigdem Agkus; Ismail Kocyigit; Oktay Oymak; Cengiz Utas
Journal:  Ther Apher Dial       Date:  2010-08-31       Impact factor: 1.762

5.  Daptomycin compatibility in peritoneal dialysis solutions.

Authors:  Laure Peyro Saint Paul; Françoise Albessard; Cathy Gaillard; Danièle Debruyne; Jean-Philippe Ryckelynck; Antoine Coquerel; Thierry Lobbedez
Journal:  Perit Dial Int       Date:  2011 Jul-Aug       Impact factor: 1.756

6.  Vancomycin-resistant enterococci peritonitis development after shifting from hemodialysis to peritoneal dialysis.

Authors:  Chih-Ming Chang; Chih-Chia Liang; Hung-Chieh Yeh; Ya-Fei Yang; I-Kuan Wang; Hsin-Hung Lin; Chiu-Ching Huang
Journal:  Ren Fail       Date:  2010       Impact factor: 2.606

Review 7.  Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them.

Authors:  William Salzer
Journal:  Perit Dial Int       Date:  2005 Jul-Aug       Impact factor: 1.756

8.  Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis.

Authors:  Sarah C Huen; Isaac Hall; Jeffrey Topal; Rex L Mahnensmith; Ursula C Brewster; Ali K Abu-Alfa
Journal:  Am J Kidney Dis       Date:  2009-02-23       Impact factor: 8.860

9.  Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient.

Authors:  Vega A Goedecke; Christian Clajus; Olaf Burkhardt; Jens Martens-Lobenhoffer; Stefanie M Bode-Boger; Jan T Kielstein; Marcus Hiss
Journal:  Scand J Infect Dis       Date:  2009

10.  Temporal trends in peritonitis rates, microbiology and outcomes: the major clinical complication of peritoneal dialysis.

Authors:  Ana Rocha; Anabela Rodrigues; Laetitia Teixeira; Maria João Carvalho; Denisa Mendonça; António Cabrita
Journal:  Blood Purif       Date:  2012-05-10       Impact factor: 2.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.